| Patient | John Henry Holliday |
|---|---|
| Date of birth | 2004-08-14 |
| Identifiers | MRN HR-NI007-SYN; SSN (made up) 000-07-8153 |
| Document date | 2026-04-14 |
| Author | Martin Beaumont, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End of the intensive phase: two-month sputum and the start of the continuation phase. [S]
Mr. Holliday returns after nine weeks of treatment. He completed the 56 doses of the intensive phase six days ago, and pyrazinamide was stopped; he now takes isoniazid, rifampin, and pyridoxine daily by video. The cultures from the third week show no growth so far, with the final reading due next week. His cough has gone, and he has gained weight. He has had no nausea, yellowing, dark urine, or numbness. He has had no alcohol for seven weeks and sees his counselor every two weeks. He is working full days. [S]
| Element | Detail |
|---|---|
| Treatment | Intensive phase complete; continuation phase started six days ago |
| Symptoms | No cough, fever, or night sweats |
| Weight | 62.5 kg, up 4.5 kg since diagnosis |
| Alcohol | None for seven weeks; AUDIT-C 1 |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum, or blood |
| Constitutional | Negative | No fever or night sweats; appetite good |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Psychiatric | Negative | Mood good; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 2026-02-12 to 2026-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 2026-02-12 to 2026-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-14 | Body height | 178 | cm | S |
| 2026-04-14 | Body weight | 62.5 | kg | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-04-14 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-04-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-14 | Heart rate | 78 | /min | S |
| 2026-04-14 | Respiratory rate | 16 | /min | S |
| 2026-04-14 | Body temperature | 36.7 | Cel | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 7-56 U/L | Normal | S |
| 2026-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 35 | U/L | 10-40 U/L | Normal | S |
| 2026-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-14 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 2026-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 62.5 kg |
| Eyes | No icterus |
| Respiratory | Clear apart from a few fine crackles at the right apex |
| Abdomen | Liver not enlarged or tender |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed | F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | No symptoms |
| Examination | Weight | At least monthly during treatment | Completed today | 62.5 kg |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | None |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 38, AST 35 U/L, bilirubin 0.7 mg/dL, all normal |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; decides the continuation length in cavitary disease | Completed today | Induced sputum smear negative today; culture sent, final reading in six weeks |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Third-week cultures show no growth so far; final next week |
| Imaging | Chest X-ray | At diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baseline | Not indicated | Not needed at two months, because the first cultures were positive |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | All 56 intensive-phase doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy |
| Referral | Contact investigation (household, coworkers, patients) | Led by the health department, from diagnosis | Referred | Health department continuing; no results are part of his record |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 1 for the past month |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Social events planned for |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Completed today | Every two weeks |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide |
| Referral | Infectious diseases review | At two months and at the end of treatment | Completed today | Dr. Navarro reviewed the plan by message today |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: End-of-treatment visit after the last dose. Monthly liver tests and symptom review in between. Call the same day for hepatitis symptoms or a returning cough. Next scheduled visit 2026-08-18: end-of-treatment review after six months. [S]